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Characterization of the T-cell epitope that causes anti-GBM
glomerulonephritis.
Background. We have demonstrated that a single T-cell epi-
tope pCol(28-40) (SQTTANPSCPEGT) alone, which is derived
from NC1 domain of a3 chain of type IV collagen (Col4a3
NC1), can induce severe glomerulonephritis in Wistar Kyoto
rats. This study further characterized this T-cell epitope.
Methods. A series of synthetic peptides derived from pCol
(28-40) were tested in vivo and in vitro for their T-cell epitope ac-
tivity and nephritogenicity. Major histocompatability complex
(MHC) class II molecules in Wistar Kyoto rats were cloned, and
MHC restriction of pCol(28-40) was determined.
Results. The T-cell epitope pCol(28-40) was restricted by
rat MHC class II RT.1Bl. Ten amino acid residues (29 to 38)
were mapped to be the minimum core of the T-cell epitope,
which was capable of inducing the T-cell response and severe
glomerulonephritis. Only three residues were identified as ab-
solutely critical for the T-cell epitope: position 31 (T) was an
anchor residue to the class II molecule, and positions 33 (N)
and 34 (P) contributed to the specificity of the T-cell epitope.
Thus, only substitution at those positions completely abrogated
nephritogenicity of the T-cell epitope. Interestingly, pCol (28-
40) also bound to human MHC class II human MHC class II
molecule HLA-DRB*1501, which has been linked to human
anti-glomerular basement membrane (GBM) disease, suggest-
ing that human homologue of pCol(28-40) could be a potential
human T-cell epitope.
Conclusion. Our study demonstrated that only few residues
in the nephritogenic T-cell epitope pCol(28-40) were critical.
Our finding also revealed that pCol(28-40) is a potential nephri-
togenic T-cell epitope in Goodpasture’s syndrome.
Anti-glomerular basement membrane (GBM)
glomerulonephritis, or Goodpasture’s syndrome, was one
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of the earliest recognized human autoimmune diseases
[1, 2]. Historically, discovery of anti-GBM antibody was
a milestone in autoimmune disease research [3]. Since
then, anti-GBM glomerulonephritis has been considered
a prototypical model for autoantibody-mediated autoim-
mune diseases [4]. Numerous studies have been devoted
to identify the causative autoantigen for anti-GBM
disease. The most notable studies were the identification
of the Goodpasture’s antigen, collagen IV a3 chain
NC domain (Col4a3NC), using patients’ antibodies
as probes [5, 6]. Later studies further demonstrated
that immunization with Col4a3NC induced anti-GBM
glomerulonephritis in several animal models [7–9].
In addition to anti-GBM antibody, many studies have
revealed that T-cell–mediated cellular immunity may po-
tentially be the most important mediator of glomeru-
lonephritis [10–12]. Inflammation with characteristics
of delayed hypersensitivity, which is typically T-cell–
mediated, has also been described in human and in ex-
perimental glomerulonephritis [13–15]. These glomeru-
lar infiltrating T cells appear to be activated as revealed
by their expression of interleukin-2 (IL-2) receptor and
various T-cell cytokines [16]. The contribution of T
cells to glomerulonephritis, especially of the prolifera-
tive/crescentic type, has been investigated in animal mod-
els either lacking T cells or with interrupted B7/CD28
costimulation pathway [17–19].
One of the most important questions regarding T-cell
involvement in glomerulonephritis, however, has been
whether antigen specific CD4+ T cells per se can tar-
get renal antigens and initiate glomerular injury. Sev-
eral groups have been searching for nephritogenic T-cell
epitopes in either human anti-GBM disease or animal
models [20–23]. We have developed a rat model for
anti-GBM glomerulonephritis, based on Col4a3NC1 [24,
25]. CD4+ T cells specific to Col4a3NC1 transferred
glomerulonephritis to naı¨ve recipients, thus providing the
first evidence that antigen-specific T cells per se initi-
ate glomerular injury [25]. This suggested that the T-cell
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Table 1. Primers for polymerase chain reaction (PCR) cloning of major histocompatability complex (MHC) class II a and b chains of Wistar
Kyoto rats
Gene Annealing T (◦C) Size bp Primer sequence
RT-1Ba 62.7 795 F AGAACAGAGATGCCGCTCAGCAGAGC
R TTCCCAGGAGTGTACTCAAAGGGGCC
RT-1Bb 62.6 809 F CTTAGAGATGGCTCTGCAGACCCCC
R CTCTCCTGTGTCACTGTAGGAGCCC
RT-1Da 55.7 815 F AGAAAATGGCCACAATTGGAGACC
R TCTTCTATGAGCTCTCACGGAAGC
RT-1Db 59.1 799 F ATGGTGTGGCTCGCCAGAGATTCC
R ACCTCAGTTCAGGAGTCCTGTTGG
epitope(s) of this glomerular autoantigen could induce
glomerulonephritis. Further, we have identified a 13-
mer peptide, pCol(28-40), of Col4a3NC1 that induced
severe glomerular injury in the experimental rats [26].
More important, autoantibody to diverse GBM antigens
was induced following T-cell–mediated glomerular in-
jury through B-cell epitope spreading [27]. Thus, a single
nephritogenic T-cell epitope is able to initiate all clinical
manifestations of anti-GBM glomerulonephritis.
In this study, we further characterized the nephrito-
genic T-cell epitope pCol(28-40). Our study revealed 10
amino acid residues to be the core of the T-cell epitope
with only three critical residues. The small size and sim-
plicity of this T-cell epitope suggest the likelihood of
molecular mimicry between the nephritogenic epitope
and microbial peptide. In addition, our study showed
that pCol(28-40) was able to bind to human major histo-
compatability complex (MHC) class II molecule HLA-
DRB∗1501, which has been linked to human anti-GBM
disease.
METHODS
Cloning of a and b chain of MHC class II molecules
Female Wistar Kyoto rats (4 to 6 weeks of age) were
purchased from Harlan (Indianapolis, IN, USA). The rats
were maintained in the animal facility at the University
of Texas Houston Health Science Center and allowed to
acclimate for a minimum of 3 days. Splenocytes were iso-
lated from the rats and were stimulated by lipopolysac-
charide (LPS) (Sigma Chemical Co., St. Louis, MO, USA)
at concentration of 10 lg/mL for 48 hours, and harvested.
Total RNA was isolated from the cells by a commercial
kit (Ambion, Austin, TX, USA), and cDNA was synthe-
sized using a reverse transcription (RT) kit (Sigma Chem-
ical Co.). Four pairs of polymerase chain reaction (PCR)
primers were designed and synthesized (Table 1) based
on the published cDNA sequence of a and b chain of
rat RT-1D and RT-1B. PCR was carried out for 30 cycles
(for the conditions, also see Table 1). The PCR products
with the expected lengths were directly cloned into vector
pTOPO/T7 (Invitrogen, Carlsbad, CA, USA). Multiple
independent clones for each chain were randomly chosen
Table 2. Synthetic peptides used in the present study
Name Residue number Sequence
pCol (28-40) 13 SQTTANPSCPEGT
pCol (30-40) 11 TTANPSCPEGT
pCol (29-39) 11 QTTANPSCPEG
pCol (28-38) 11 SQTTANPSCPE
pCol (29-38) 10 QTTANPSCPE
and sequenced. The sequences were compared with the
published data including those in GeneBank.
Antigen preparation
Peptides were synthesized on an automatic peptide
synthesizer, AMS 422 (Gilson, Middleton, WI, USA) us-
ing Fmoc chemistry and were purified by reverse phase
C18 column on a preparative high-performance liquid
chromatography (HPLC) (Water, Millford, MA, USA).
Purified peptides were analyzed by HPLC for purity and
by mass spectrometry for the correct sequence. Peptides,
exceeding 95% purity, were dissolved in milli-Q water at
1 mmol/L concentration, and used for immunization or
other investigative purposes. The sequences of synthe-
sized peptides are listed in Table 2.
Immunization and glomerulonephritis evaluation
Female Wistar Kyoto rats (4 to 6 weeks of age) were
allowed to acclimate for a minimum of 3 days. Rats (6 to
12 rats/group or as stated) were immunized with a peptide
(0.125 lmol) emulsified in complete Freund’s adjuvant
(CFA), in one hind footpad and at the base of tail. Rats
immunized with CFA alone, or with an irrelevant peptide
CP2 [26] served as controls.
Glomerulonephritis was evaluated by measurement
of proteinuria/albuminuria and examination of renal
histopathology. Random urine samples were monitored
daily by Multstix (Bayer, Pittsburgh, PA, USA). Urine
albumin was semiquantitated by 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
(2 lL urine/lane) using bovine serum albumin (BSA)
as a standard. The experimental animals were sacrificed
as indicated. Kidney tissues fixed in Bouin’s solution
were used for hematoxylin and eosin staining or periodic
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acid-Schiff (PAS) staining [24]. Glomeruli with cresentic
lesions, hypercellularity, or without injury were counted
separately, and glomerular injury score was calculated as
following:
(number of crescentic glomeruli × 100) ± ( number of hypercullular glomeruli × 50)
total number of glomeruli
Student t test was carried out to compare the score be-
tween an experimental group and the group immunized
with pCol(28-40). P values were indicated as P < 0.01
or P < 0.001. A portion of the kidney tissues was snap-
frozen in liquid nitrogen for direct immunofluorescence
staining [27].
Generation of T-cell lines specific to pCol(28-40)
Wistar Kyoto rats were immunized with pCol(28-40)
as described above and sacrificed at day 20. Lympho-
cytes were isolated from inguinal lymph nodes, adjusted
to 2 × 106 cells/mL, and stimulated by pCol(28-40) at a
10 lmol/L for 4 days in a medium described previously
[25]. The cells were harvested and allowed to rest for
7 days in the presence of mouse IL-2 (10 ng/mL) gener-
ated from EL4 cell line (ATCC, Manassas, VA, USA).
The cells were adjusted to 0.5 × 106 cells/mL, restimu-
lated with 10 lmol/L pCol(28-40) in the presence of ir-
radiated thymocytes (2 × 106 cells/mL) from a normal
Wistar Kyoto rat (1000 rad) for 4 days, and then allowed
to rest. The stimulation/resting cycle was repeated more
than three times, and samples of the cells were stained
with anti-CD4 and anti-CD69 antibodies for flow cytom-
etry. CD4+/CD69+ cells were considered as antigen spe-
cific CD4+ T cells.
Lymphocyte proliferation assay (LPA)
LPA was carried out as previously described [24, 25].
Briefly, lymphocytes were prepared from immunized
rats, and CD3+ T cells were isolated with a T-cell enrich-
ment column (RTCC) (R&D Systems, Minneapolis, MN,
USA). The purity of isolated T cells was determined
by flow cytometry analyses (FACSCalibur) (Becton
Dickinson, San Jose, CA, USA) after staining with anti-
CD4 phycoerythrin (PE) and antirat IgM/G-fluorescein
isothiocyanate (FITC) antibodies (Pharmingen, San
Diego, CA, USA). T cells and irradiated syngeneic
thymocytes (1:1) were cultured in 96-well plates at 4 ×
105 cells/well in 200 lL of complete T-cell medium
described previously. Peptides at various concentrations
(0.3 to 30 lmol/L) were added to wells in triplicate, and
purified protein derivative (PPD) was used as a positive
control. When a T-cell line was used, 2 × 103 T cells
were added to each well under the same conditions
described above. The cells were incubated at 37◦C in a
humidified, 5% CO2 atmosphere for 72 hours, pulsed
with 3[H]-thymidine (0.5 lCi/well) for 18 hours (ICN,
Costa Mesa, CA, USA), and harvested onto glass fiber
filters using a semiautomatic cell harvester (Skatron
Instruments, Sterling, VA, USA). The incorporated ra-
dioactivity was measured by a liquid scintillation counter
(Beckman, Fullerton, CA, USA). The results were ex-
pressed as cpm (mean triplicate cpm with antigen minus
mean triplicate cpm without antigen), or as the stimula-
tion index (ratio between cpm with and without antigens).
Determination of MHC class II restriction
Two methods were used to determine MHC class II
restriction of pCol(28-40). First, two antibodies to RT.1B
(OX6) and RT.1D (OX17), both from Pharmingen (San
Diego, CA, USA), were tested, respectively, for their abil-
ities to inhibit activation of pCol(28-40)–specific T cells
in the presence of pCol(28-40). Using the identical LPA
as described above, the antibody (10 lg/mL) was added
to each well, and proliferation of pCol(28-40)–specific
T cells was determined. In parallel, wells with normal
mouse IgG, or without antibody, served as controls. Sec-
ond, 30 lmol/L of FITC-labeled pCol(28-40) was in-
cubated with isolated splenic macrophages at 4◦C for
6 hours. Splenic macrophages from BN/SsNHsd rats
(RT.1u) were used as a negative control. After washing
and fixation in 2% paraformaldehyde, binding of FITC-
pCol(28-40) to the cell surface was examined by confocal
microscopy.
In vitro binding of pCol(28-40) to human MHC class II
molecules
T-cell epitope pCol(28-40) was also tested for their
binding affinity to a series of human MHC class II
molecules by in vitro binding assay. A set of human class II
molecules that included 7 HLA-DR molecules was tested
following a well-established method [28]. Briefly, various
concentrations of the peptide were allowed to compete
with a standard peptide for binding to a class II molecule
that had been labeled with radioactive isotope. Binding
affinity of the peptide to a human MHC class II molecule
was expressed as that concentration which led to a 50%
reduction in binding of the standard peptide.
Detection of antibody activity
A previously described enzyme-linked immunosor-
bent assay (ELISA) method was applied to detect an-
tibodies to peptides [26]. Briefly, plates were coated
with 50 lL peptide of 10 lmol/L in a carbonate buffer
(pH 9.5). Serially diluted serum (100 to 800) was added
to each well in duplicate. The bound rat IgG antibodies
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were detected with horseradish peroxidase–labeled goat
antirat IgG (1:10,000) (Southern Biotechnology, Birm-
ingham, AL, USA) using O-phenoldiamine (0.25 mg/mL)
as the substrate. The plates were read on an ELISA reader
(Molecular Devices, Sunnyvale, CA, USA) at 490 nm.
Direct immunofluorescence was carried out to detect
anti-GBM antibody which bound to GBM in vivo [27],
using FITC-labeled goat antirat IgG or IgM antibod-
ies (1:50) (Southern Biotechnology). The stained sec-
tions were viewed with a fluorescence microscope (BH-2,
Olympus).
RESULTS
Cloning of RT.1D and RT.1B of Wistar Kyoto rat
Although Wistar Kyoto rats have been used in several
animal models of glomerulonephritis, their MHC class
II molecules have not been characterized or cloned. The
a and b chain of both RT.1B and RT.1D were cloned
by RT-PCR using cDNA from LPS-stimulated spleno-
cytes. Multiple independent clones for each chain were
sequenced. A search of GeneBank showed that the a
and b chains of RT.1B or RT.1D were both identical
to those of Lewis rats, and thus both belong to pheno-
type l (29-31) (for RT.1Da, GeneBank gi 40556828). The
cDNA sequences of all four chains have been submitted
to GeneBank (bankit651498 AY701537; bankit651504
AY701538; bankit651510 AY701539; and bankit651512
AY701540).
MHC class II restriction of nephritogenic T-cell epitope
pCol(28-40)
Peptide pCol(28-40), derived from Goodpasture’s anti-
gen, collagen IV a3 (NC domain of a3 chain of type
IV collagen), is a 13-mer peptide, which induces severe
glomerulonephritis in Wistar Kyoto rats. Two indepen-
dent T-cell lines specific to pCol(28-40) were generated
from Wistar Kyoto and tested for MHC class II restric-
tion. In both lines, antibody to RT.1B (OX6) completely
inhibited T-cell proliferation (Fig. 1A). In contrast, pro-
liferations of T cells in all other groups, including those
with antibody to RT.1D (OX17), normal mouse IgG, or
without any antibody, were essentially the same (Fig. 1A).
Thus, antibody to RT.1D failed to inhibit T-cell prolifera-
tion. Those results demonstrated that the nephritogenic
T-cell epitope pCol(28-40) is restricted by RT.1Bl. The
binding of pCol(28-40) to MHC class II of Wistar Kyoto
was also demonstrated by an in vitro binding test. We have
synthesized FITC-labeled pCol(28-40) and observed that
it was able to bind to the surface of macrophages isolated
from Wistar Kyoto spleen by the adhesion (Fig. 1B). Such
binding could be inhibited by addition of overdose of
nonlabeled pCol(28-40). In contrast, the peptide failed
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Fig. 1. Major histocompatability complex (MHC) class II restriction
of T-cell epitope pCol(28-40). (A) T cells specific to pCol(28-40) are
tested against pCol(28-40) using thymocytes as antigen-presenting cells
in the presence of antibody to RT1.B or RT1.D; T-cell proliferation is
measured by up-take of 3[H]-labeled thymidine. (B) Confocal micro-
graph showing binding of fluorescein isothiocyanate (FITC)-labeled
pCol(28-40) to splenic macrophages from Wistar-Kyoto rat, but not to
the macrophages from BN/SsNHsd rat (C).
to bind to splenic macrophages from BN/SsNHsd strain
(Fig. 1C).
Position 29 to 38 is the core region of the nephritogenic
T-cell epitope pCol(28-40)
A typical T-cell epitope, which binds to a MHC class
II molecule, may be composed of as few as 9 to 11 amino
acid residues. We decided to map the minimum core
residues in the nephritogenic T-cell peptide pCol(28-40).
Three 11-mer peptides were synthesized to cover the
C-terminus, N-terminus, or central part of pCol(28-40)
(Table 2). The peptides were first tested against CD4+
T-cell lines specific to pCol(28-40) by T-cell proliferative
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Fig. 2. T-cell epitope activity and nephritogenicity of three 11-mer peptides derived from pCol(28-40). (A) Response of pCol(28-40)–specific T cells
to different peptides as indicated; T-cell responses are expressed as T-cell proliferation. (B) T-cell response to pCol(28-40) in the rats immunized with
each of three 11-mer peptides as indicated. (C) Glomerulonephritis in the rats immunized with indicated peptides; severity of glomerulonephritis
is expressed as average glomerular injury scores from 10 individuals.
assay. Although all three peptides induced T-cell prolifer-
ation, the responsiveness of T cells to the three peptides
varied significantly. Both pCol(28-38) and pCol(29-39)
showed strong stimulation of pCol(28-40) specific T cells
to proliferate, but pCol(30-40) only induced very poor
T-cell proliferation, with more than 30-fold lower sen-
sitivity as compared with the other two peptides
(Fig. 2A).
The peptides were then tested in vivo. Wistar Kyoto rats
were immunized with each of the three peptides, respec-
tively, and T-cell responses and glomerulonephritis in the
immunized rats were examined. T cells from pCol(30-
40)–immunized rats weakly responded to pCol(28-40)
(Fig. 2B), and only about 20% of the immunized animals
developed severe glomerulonephritis. On the other hand,
both pCol(28-38) and pCol(29-39) elicited a strong T-cell
response to themselves as well as to pCol(28-40). More
importantly, both pCol(28-38) and pCol(29-39) induced
severe glomerulonephritis in 100% of the immunized rats
(Fig. 2C). Although there was no significant statistical dif-
ference, pCol(28-38) seemed to be at least as potent in
induction of glomerulonephritis as pCol(28-40). Based
on the above results, a 10 amino acid peptide, pCol(29-
38), was synthesized and tested both in vitro and in vivo
(Fig. 3). As we expected, the 10-mer peptide pCol(29-
38) was able to stimulate pCol(28-40)–specific T cells to
proliferate (Fig. 3B). Immunization with pCol(29-38) not
only induced a T-cell response to both pCol(28-40) and
pCol(29-38) (Fig. 3A), but also led to severe proteinuria
and glomerular injury in all immunized animals (Fig. 3C
and D). Interestingly, anti-GBM antibody of IgG type was
detectable in the immunized rats by direct immunofluo-
rescence (Fig. 3E) (Table 3), although this peptide failed
to induce any antibody response to itself. We concluded
that the 10 amino acid residues from position 29-38 is
the minimum core for the nephritogenic T-cell epitope
pCol(28-40), which lacks any B-cell epitopes.
Mapping critical residue of the T-cell epitope
The critical residues for T-cell epitope in pCol(28-40)
were mapped using a set of alanine/glycine substituted
peptides. These peptides were designated as pCol28A
to pCol40A based on the position and the substituting
residues. For example, pColA40 was the peptide with a
single substitution at positive 40 with an alanine. First,
pCol(28-40)-specific CD4+ T cells were tested for their
reactivity against this set of peptides (Fig. 4A). pCol(28-
40)–specific T cells completely failed to respond the
peptides pCol31A, 33A, and 34A, suggesting that the
residues 31, 33, and 34 may be critical for T-cell epi-
tope. However, T cells showed much lower sensitivities
to pCol30A, suggesting that this residue may be also im-
portant.
Next, each of the substituted peptides was used to
immunize rats. Immune responses and development of
glomerulonephritis in the immunized animals were de-
termined. The results are summarized in Figure 4B and
C. T cell responses to the wild peptide pCol(28-40) as
well as the immunizing substituted peptide in the immu-
nized animals were measured (Fig. 4B). Based on the
T-cell response pattern in the immunized rats, the substi-
tuted peptides were categorized into four groups. The
first group, which included pCol28A, 29A, 32A, 36A,
37A, 38A, 39A, and 40A, provoked a T-cell response
reactive not only with the immunizing substituted pep-
tides but also with wild peptide pCol(28-40). The sec-
ond group, which included pCol33A and 34A, induced a
strong T-cell response to themselves but not to pCol(28-
40) (also see Fig. 5B and C). The third group, pCol31A,
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Fig. 3. T-cell response and glomerulonephritis induced by 10-mer peptide pCol(29-38). (A) Response of pCol(29-38)–specific T cells against
pCol(28-40) and pCol(29-38). (B) Response of pCol(28-40)–specific T cells against pCol(28-40) and pCol(29-38); T-cell response to an irrelevant
peptide CP2 is also shown. (C) Glomerulonephritis induced by pCol(29-38); severity of glomerulonephritis expressed as glomerular injury score;
each open circle represents one experimental rat; horizontal bars indicate group averages (N= 10) (P = 0.45). (D) Renal histopathology showing
glomerular injury in a rat immunized with pCol(29-38). The arrows delineate the cellular crescent and the asterisk overlies the injured and collapsed
glomerular capillary tuft (bar = 50 lm). (E) Direct immunofluorescence on renal tissue of a pCol(29-38)–immunized rat showing linear binding of
IgG to fragmented glomerular basement membrane (GBM).
failed to induce any T-cell response (also see Fig. 5A). The
fourth group including two peptides, pCol30A and 35A,
induced modest T-cell response to themselves, which
weakly cross-reacted with pCol(28-40) (Fig. 4B). Devel-
opment of glomerulonephritis in the immunized rats was
examined. Substitutions at positions 28, 29, 32, 36, 37, 38,
39, and 40 had no significant affect on nephritogenicity
of the peptide, while the substitutions at positions 30 and
35 significantly reduced the severity of induced glomeru-
lonephritis (Fig. 4C). In contrast, substitution at positions
31, 33, and 34 completely abrogated the peptide’s abil-
ity to induce glomerulonephritis (Fig. 4C). Importantly,
the potency of a peptide with single substitution in in-
duction of glomerulonephritis was correlated only with
T-cell reactivity to pCol(28-40) but not with immunizing
peptides. Thus, pCol33A and pCol34A, which induced T-
cell responses only to themselves (Fig. 5B and C), failed
to induce any renal pathology.
Antibody responses to peptides
pCol(28-40) contains a peptidic B-cell epitope [23, 24].
Antibody to pCol(28-40) reacted with all substituted pep-
Table 3. IgG glomerular basement membrane (GBM) antibody in
rats immunized with derivatives of pCol(28-40) as detected by direct
immunofluorescence
Fluorescent density
Species Peptide Number 0 1+ 2+ 3+
Wistar-Kyoto pCol(28-38) 12 2 1 8 1
pCol(29-39) 12 1 0 9 2
pCol(30-40) 14 10 1 3 0
pCol(29-38) 10 2 0 7 1
pCol34A 12 12 0 0 0
pCol40A 12 2 1 9 0
Lewis pCol(28-40) 12 12 0 0 0
tides except pCol37A, 39A, and 40A, suggesting that
those residues are critical for the B-cell epitope encoded
in pCol(28-40). Specificity of antibody elicited by each of
substituted peptides was determined. Antibody reactivity
to the immunizing peptide as well as pCol(28-40) in the
immunized rats were measured by ELISA and summa-
rized in Figure 6. Most of peptides induced an antipeptide
antibody response, which cross-reacted with pCol(28-
40). Antibody elicited by peptides pCol36A, 38A, and
40A displayed a much lower reactivity to pCol(28-40).
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Fig. 4. Cross-reactivity with T-cell epitope pCol(28-40), induction of
T-cell responses, and nephritogenicity of the set of peptides with single
substitution at each position of pCol(28-40). X axis indicates the posi-
tion of the substituted residues. (A) Response of pCol(28-40)–specific T
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residues against the immunogens (◦) or pCol(28-40) (•). Horizontal line
indicates the average of T-cell response in pCol(28-40)–immunized rats
to pCol(28-40). (C) Glomerulonephritis in the rats immunized with se-
rial peptides with substituted residues; severity of glomerulonephritis
is expressed as average of glomerular injury scores of each peptide (six
rats/peptide).
Antibody response in the rats immunized with the mini-
mum core of the T-cell epitope pCol(29-38) was also ex-
amined. pCol(29-38) failed to induce any antibody re-
sponse to itself or to pCol(28-40) (data not shown). Thus,
pCol29-38 may not contain any B-cell epitope. There was
no correlation between the anti-peptide antibody and
severity of glomerulonephritis. For example, pCol40A,
a potent nephritogenic peptide (Fig. 6B), failed to elicit
antibody to pCol(28-40), while pCol34A, which did not
induced any glomerular damage, induced a high titer an-
tibody to pCol(28-40). Anti-GBM antibody, which bound
to GBM in vivo, was observed only in the rats immunized
with substituted peptides which induced severe glomeru-
lonephritis (Fig. 6B) (Table 3).
pCol(28-40) binds to human HLA-DRB∗1501
Using an in vitro binding assay, pCol(28-40) was tested
for its binding affinity to a set of human MHC class
II molecules (Table 4). Nephritogenic T-cell epitope
pCol(28-40) showed a modest binding affinity only to hu-
man HLA-DRB∗1501 and no affinity to any other tested
class II molecules.
DISCUSSION
We have previously demonstrated that a T-cell–
mediated mechanism is alone able to induce anti-GBM
glomerulonephritis [25]. We have further identified a
T-cell epitope pCol(28-40) of 13 amino acid from Good-
pasture’s antigen collagen IV a3 (a3 chain of type IV col-
lagen) that induce extremely severe glomerulonephritis
[26]. In the present study, the nephritogenic T-cell epi-
tope pCol(28-40) was further characterized in detail. Our
study revealed 10 amino acid residues from position 29 to
38 to be the core of the T-cell epitope, which was able to
induce severe glomerulonephritis and a T-cell response
to pCol(28-40). Only three amino acid residues (positions
31, 33, and 34) were identified as critical, and only two
(positions 30 and 35) were semi-critical for the T-cell epi-
tope.
Based on the results from the present study, especially
those from the experiments using the set of peptides with
single amino acid substitution, we have been able to de-
termine the role of each critical or semi-critical residues in
nephritogenic T-cell epitope pCol(28-40) (Fig. 7). Among
three critical residues (position 31, 33, and 34), position
31 is an anchor residue to RT.1Bl, since substitution at this
position resulted in loss of T-cell epitope activity. Thus,
pCol31A failed to induce any T-cell response. On the
other hand, peptides with substitution at position 33 and
34 induced strong T-cell responses. However, the T cells
only reacted with the peptide themselves, but not with
pCol(28-40). Those results demonstrated that positions
33 and 34 contribute to the specificity of the T-cell epi-
tope pCol(28-40). Beside the three most critical residues
for the T-cell epitope, positions 30 and 35 are considered
to be semi-critical; peptides with substitutions at those
positions led to either reduced activity or slightly altered
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Fig. 5. T-cell response in the rats immunized with pCol31A (A), pCol33A (B), and pCol34A (C). T cells were tested against pCol(28–40) (•) and
immunizing peptides (◦) as indicated.
specificity to T-cell epitope pCol(28-40). Obviously, posi-
tions 28, 39, and 40 are outside of RT.1Bl, and thus are not
involved in binding or specificity. However, those partic-
ular residues may modulate binding affinity. For example,
substitution at position 40 led to a significantly enhanced
T-cell response.
Clearly, the nephritogenicity of the peptides now can be
ordered from more to less potent as follows: pCol(28-40)
= pCol(29-39) ≥ pCol(28-38) ≥ pCol(29-40) ≥ pCol(29-
38) >> pCol(30-40) >> pCol(19-38). In our previous pa-
per, we believed that residues 39 and 40 were important
because that pCol(28-40) was much more potent than
pCol(19-38) [26]. This raises an interesting question. Why
is pCol(19-38) the least potent since it contains the core
pCol(29-38)? This probably can be answered by the con-
cept of the so-called cryptic T-cell epitope. A cryptic T-
cell epitope is normally not presented by the antigen-
presenting cells [33]. However, a synthetic peptide may
expose the cryptic epitope. If pCol(19-38) also encodes a
nested nonpathogenic cryptic T-cell epitope, it may show
a higher affinity to MHC class II molecules and thus com-
plete with the nephritogenic T-cell epitope pCol(29-38).
The present study again demonstrated that a T-cell
epitope pCol(28-40) alone can cause anti-GBM glomeru-
lonephritis. Substitutions at positions 33 and 34 resulted
in altered specificities of the T-cell epitope, and thus the
peptides with substitution at 33 and 34 failed to induce
any glomerular injury. In fact, the severity of glomeru-
lonephritis in the immunized rats correlated highly with
the cross-reactivity of the substituted peptide-reactive
T cells with the wild peptide pCol(28-40). In contrast,
antibody response to the wild peptide pCol(28-40),
elicited by substituted peptide, showed no correlation
with nephritogenicity of the peptide. More important,
pCol(29-38) (minimum core of the T-cell epitope), which
induced severe glomerulonephritis, failed to induce anti-
body to itself, suggesting that it encodes no B-cell epitope.
However, pCol(29-38), despite lacking any B-cell epi-
topes, induced not only severe glomerular injury, but also
IgG type anti-GBM autoantibody. This result supported
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Fig. 6. Antibody response and B-cell epitope specificity of the set of
peptides with single residue substitution at each position of pCol(28-
40). X axis indicates the position of the substituted residue. (A) Reac-
tivity of pCol(28-40)–specific antibody to the serial peptides with sub-
stituted residues; the antibody activity was measured by enzyme-linked
immunosorbent assay (ELISA). (B) Antibody response elicited by
each peptide; antibody to pCol(28-40) or immunizing peptide was mea-
sured by ELISA; direct immunofluorescence of linear binding of anti-
glomerular basement membrane (GBM) antibody to GBM is shown
(, positive; , negative).
our previous findings that a single self T-cell epitope alone
is able to trigger an autoantibody response to diverse tar-
get autoantigens through B-cell epitope spreading [27,
32]. Thus, a nephritogenic T-cell epitope, which may be
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Table 4. Binding affinity of pCol(28-40) to human major
histocompatability complex (MHC) class II molecules
Human MHC class II IC50 nmol/L
DRB1∗0101 >15,000
DRB1∗0401 >15,000
DRB1∗0701 >15,000
DRB1∗0802 >120,000
DRB1∗1302 >15,000
DRB1∗1501 399
DRB4∗0101 >15,000
DRB5∗0101 >15,000
TcR
30T
29Q28S
35S
36C
37P 38P 39g 40t
32A
31T
33N 34P
RT.1B
Fig. 7. Schematic diagram of the structure of the nephritogenic T-cell
epitope pCol(28-40). Closed circles are critical residues, while semi-
critical residues are indicated by gray color; lower case letters represent
residues that are probably outside of major histocompatability complex
(MHC) class II molecule RT.1Bl.
composed of as few as 10 amino acids, is sufficient to
initiate all clinical manifestations of anti-GBM disease,
including glomerular injury, proteinuria, and anti-GBM
antibody.
Our study has shown only three residues in nephrito-
genic T-cell epitope pCol(28-40) to be absolutely critical.
This suggests a possibility of molecular mimicry between
the nephritogenic epitope and microbial peptide. Several
prior studies have proposed molecular mimicry as a link
between infections and glomerulonephritis without any
experimental support [34]. Molecular mimicry has been
suspected as a possible mechanism for breaking immune
tolerance and causing human autoimmune diseases [35,
36]. T-cell epitope mimicry is more realistic, since only 3
to 5 residues were critical for a nephritogenic T-cell epi-
tope as we have shown in this study. It remains a question
whether T-cell epitope mimicry is the cause of anti-GBM
glomerulonephritis. Our findings may provide some sci-
entific bases for this possibility.
A strong association between Goodpasture’s disease
and HLA class II allele HLA-DRB∗1501 has been re-
ported [37–40], suggesting that DRB∗1501 is responsi-
ble for presentation of autoantigen Col4a3NC1. Several
groups have been searching for potentially pathogenic T-
cell epitope associated with DRB∗1501 by either direct
HLA binding assay or measuring peripheral T-cell re-
sponses to those peptides [20–23, 41]. Our finding that
pCol(28-40) binds to HLA-DRB∗1501 with a modest
affinity may provide more information. We also realize
that human and rat sequences differ by one residue at po-
sition 33, which is an isoleucine in human but asparagine
in rats [42]. In addition, a 20-mer peptide containing this
region of human sequence has been tested [43]. None
of the six Goodpasture patients’ peripheral T cells re-
sponded to this peptide. However, whether weak specific
proliferative responses of peripheral T cells are true re-
flection of a T-cell–mediated attack in the glomerulus is
unclear [44]. This is perhaps the most challenging aspect
for any human autoimmune disease study.
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